SPARC and colorectal carcinoma: When patients were further divided into stage II and III disease with either a good or a poor outcome, SPARC expression was significantly greater in patients with a good disease outcome in stage II CRC (p = 0.0039; Figure 3C), however, no statistical difference was observed between the groups in stage III CRC (Figure 3D).